CAM
ELTX icon

Cresset Asset Management’s Elicio Therapeutics ELTX Stock Holding History

Cresset Asset Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Buy
+11,425
New +$110K ﹤0.01% 1521
2025
Q4 		– Sell
-26,925
Closed -$295K – 1671
2025
Q3 		$295K Buy
+26,925
New +$272K ﹤0.01% 1248

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cresset Asset Management's ELTX Position: Q1 2026 in Review

Cresset Asset Management opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 11,425 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #1521 among its holdings. This is a return to the name: Cresset Asset Management previously reported a position in ELTX as recently as Q3 2025.

Cresset Asset Management first reported a position in ELTX in Q3 2025 and has held it in 2 quarters since. The position peaked at $295K in Q3 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Cresset Asset Management held 11,425 shares of Elicio Therapeutics worth $122K as of Q1 2026.
  • Elicio Therapeutics was a new Cresset Asset Management position in Q1 2026.
  • Elicio Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1521 holding.
  • Cresset Asset Management first reported a position in Elicio Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Cresset Asset Management's Elicio Therapeutics position peaked at $295K in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.